The primary objective is to describe the genomic profile of long-term survivors, especially to find out potential genomic prognosis and/or predictive factors for gefitinib long-term efficacy as compared to rapid PD patients
Study Type
OBSERVATIONAL
Enrollment
59
Research Site
Beijing, Beijing Municipality, China
Research Site
Fuzhou, Fujian, China
Research Site
Guangzhou, Guangdong, China
Proportion of patients with specific genomic alterations(mutation, copy number change and fusion) of short or long-term survivors
Time frame: at time of sample collection before Gefitinib treatment initiation, up to 10 years before study start
Sex
Time frame: at time of Gefitinib treatment initiation,up to 10 years before study start
Age
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Pre-existing comorbidities at initiation of gefitinib therapy
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Cancer type and date of first ever cancer diagnosis
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Histological subtype
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Location(s) of metastatic disease at initiation of gefitinib therapy for subjects with TNM stage IV disease
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
EGFR mutation status
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Smoking status
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Shijiazhuang, Hebei, China
Research Site
Zhengzhou, Henan, China
Research Site
Wuhan, Hubei, China
Research Site
Nanjing, Jiangsu, China
Research Site
Changchun, Jilin, China
Research Site
Shenyang, Liaoning, China
Research Site
Xi'an, Shaanxi, China
...and 4 more locations
ECOG performance status at time of Gefitinib treatment initiation
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Gefitinib treatment patterns- Starting dose
Time frame: at time of Gefitinib treatment initiation, up to 10 years before study start
Gefitinib treatment patterns- Dose reductions, treatment interruptions, discontinuation including reasons
Time frame: from Gefitinib treatment initiation to Gefitinib treatment discontinuation or study completion, whichever occurred first, up to 12 years
Gefitinib treatment patterns- Types of other systemic therapies given in combination with gefitinib
Time frame: from Gefitinib treatment initiation to Gefitinib treatment discontinuation or study completion, whichever occurred first, up to 12 years
Therapeutic agent name post-gefitinib discontinuation
Time frame: from gefitinib discontinuation to one year post- gefitinib discontinuation, around one year
Documented tumour response (complete or partial response or stable disease, according to RECIST) as determined by the treating physician by clinical judgment and/or imaging after first ever initiation of gefitinib
Time frame: from Gefitinib treatment initiation to study completion, up to 12 years
Progression Free Survival (PFS)
Time frame: from Gefitinib treatment initiation to disease progression or study completion, whichever occurred first, up to 12 years
Overval survival (OS)
Time frame: from Gefitinib treatment initiation to death or study completion, whichever occurred first, up to 12 years